title: [Neuroendocrine carcinoma of the bladder: A single centre retrospective study].
abstract: OBJECTIVE
  Neuroendocrine carcinoma of the bladder is a rare tumour representing 0.5 to 1% of bladder tumours. It is a specific histological entity characterized by rapid metastatic dissemination and poor prognosis. The aim of this study was to describe the epidemiological, clinical, therapeutic modalities and the evolutive aspects of patients receiving a treatment for bladder neuroendocrine carcinoma.
  
  
  METHODS
  Between January 2004 and January 2014, seven patients received a treatment for a neuroendocrine carcinoma of the bladder, at the department of oncology, Habib-Bourguiba Hospital, in Sfax, Tunisia.
  
  
  RESULTS
  The median age was 58 years. All patients were male. Neuroendocrine carcinoma was pure in four cases and associated with urothelial carcinoma in the other three cases. Two patients were diagnosed at a metastatic stage. A cystectomy was performed in two cases. One patient received a chemotherapy and radiotherapy. The other four patients received chemotherapy alone. A single case of complete remission was observed. Median survival was 15 months (5-30 months). One patient is still alive 30 months after diagnosis.
  
  
  CONCLUSIONS
  The management of neuroendocrine carcinoma of the bladder is not standardized and requires a multidisciplinary consultation.
authors.affiliation: Service de carcinologie médicale, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
authors.forename: I
authors.initials: I
authors.lastname: Ayedi
authors.affiliation: Service de carcinologie médicale, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
authors.forename: I
authors.initials: I
authors.lastname: Abdelli
authors.affiliation: Service de carcinologie médicale, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie. Electronic address: hamedchaabouni.hc@gmail.com.
authors.forename: H
authors.initials: H
authors.lastname: Chaabouni
authors.affiliation: Service d'anatomopathologie, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
authors.forename: S
authors.initials: S
authors.lastname: Charfi
authors.affiliation: Service de carcinologie médicale, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
authors.forename: A
authors.initials: A
authors.lastname: Khanfir
authors.affiliation: Service de carcinologie médicale, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
authors.forename: N
authors.initials: N
authors.lastname: Toumi
authors.affiliation: Service d'urologie, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
authors.forename: N
authors.initials: N
authors.lastname: Mhiri
authors.affiliation: Service de radiothérapie, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
authors.forename: J
authors.initials: J
authors.lastname: Daoud
authors.affiliation: Service de carcinologie médicale, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
authors.forename: M
authors.initials: M
authors.lastname: Frikha
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D020295:Brain Stem Neoplasms / Q000556:secondary; D018278:Carcinoma, Neuroendocrine / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D015653:Cystectomy; D006417:Hematuria / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D019459:Urothelium / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents
keywords: Bladder; Cancer; Neuroendocrine; Prognosis; Pronostic; Traitement; Treatment; Vessie